Division of Regenerative Medicine Support
We support research and development of cellular products and regenerative medical products conducted on campus, at other universities, and at off-campus medical institutions. We strive to deliver regenerative medical products to patients promptly by providing a wide range of support, from basic research on various diseases, pathological conditions, and physiological phenomena conducted mainly in academia, to clinical research using cellular products and regenerative medical products already in use overseas.
The Regenerative Medicine Support Division (RM Division) consists of the following three units, each of which provides operational support.
Projects related to the Division of Regenerative Medicine Support, etc.
RM Support Unit
Role
In response to various needs at each development stage, we support researchers from application for research grants to first-in-human (FIH) clinical trials.
RM Administration Unit
Role
The RM Administration Unit support both IND and non-IND clinical research projects to comply with the regulatory requirements (e.g., applicable laws, ethics guidelines and institutional SOPs) to secure academic achievements and to improve R&D efficiency. Also, the unit provides valuable advises to promote good communication with regulatory authorities, IRBs and institutions and to accelerate preparation of essential documents.
Cell Processing Support Unit
Role
The Cell Processing Support Unit provides the facility for manufacturing cell products for clinical trials. It also supports administrative work related to manufacturing.
Please click the link below to see our cell processing facility.
Projects related to the Division of Regenerative Medicine Support, etc.
We are developing the following two projects related to regenerative medicine.
Establishment of model hospital for clinical trial of regenerative medicine in eastern Japan
We are working to establish "Model hospital for clinical trial of regenerative medicine " that is capable of supporting and accepting clinical research requiring advanced technology such as induced pluripotent stem cell research and Investigator-initiated clinical trials.
Project to accelerate the stable provision of stem cell materials in regenerative therapy products
We are working to establish a system to continuously and stably supply human (allogeneic) somatic stem cell materials that can be used for the manufacture of regenerative medical products to pharmaceutical companies and other institutes.
For more information, please see the following pages.